-
UPDATE: Citi Upgrades Spark Therapeutics (ONCE) to Buy, Sees M&A Value Upwards of $130/Share
-
Spark Therapeutics (ONCE) Should Not Trade Higher on Biomarin (BMRN) Heme Data Update - Citi
-
BioMarin Pharma (BMRN) Should Not Be Selling Off on Heme Data - Citi
-
Citi Starts Spark Therapeutics (ONCE) at Neutral
-
Pre-Open Movers 01/16: (HAWK) (CATS) (MRK) Higher; (EIGR) (DPW) (KODK) Lower (more...)
-
Pre-Open Movers 12/12: (PTI) (RPRX) (GLYC) Higher; (PPHM) (MARA) (CASY) Lower (more...)
-
Pre-Open Stock Movers 06/14: (VG) (TLRD) (NXPI) Higher; (INFI) (MESO) (KMPH) Lower (more...)
-
Notable Analyst Rating Changes 3/31: (OIS) (MT) (FTNT) Upgraded; (TGT) (RAX) (SQ) Downgraded
-
Notable Analyst Rating Changes 3/22: (WYNN) (AIG) (PBR) Upgraded; (EPE) (CPA) (INFI) Downgraded
-
Notable Analyst Rating Changes 2/19: (COH) (VLO) (MWW) Upgraded; (I) (PCYC) (HUN) Downgraded